Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial.
Ross AM, Coyne KS, Moreyra E, Reiner JS, Greenhouse SW, Walker PL, Simoons ML, Draoui YC, Califf RM, Topol EJ, Van de Werf F, Lundergan CF. Ross AM, et al. Among authors: van de werf f. Circulation. 1998 Apr 28;97(16):1549-56. doi: 10.1161/01.cir.97.16.1549. Circulation. 1998. PMID: 9593559 Clinical Trial.
Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.
Barbash GI, Birnbaum Y, Bogaerts K, Hudson M, Lesaffre E, Fu Y, Goodman S, Houbracken K, Munsters K, Granger CB, Pieper K, Califf RM, Topol EJ, Van De Werf F. Barbash GI, et al. Among authors: van de werf f. Circulation. 2001 Feb 20;103(7):954-60. doi: 10.1161/01.cir.103.7.954. Circulation. 2001. PMID: 11181469
Bolus fibrinolysis: risk, benefit, and opportunities.
Armstrong PW, Granger C, Van de Werf F. Armstrong PW, et al. Among authors: van de werf f. Circulation. 2001 Feb 27;103(8):1171-3. doi: 10.1161/01.cir.103.8.1171. Circulation. 2001. PMID: 11222483 No abstract available.
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van De Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ. Newby LK, et al. Among authors: van de werf f. Circulation. 2001 Jun 19;103(24):2891-6. doi: 10.1161/01.cir.103.24.2891. Circulation. 2001. PMID: 11413076 Clinical Trial.
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network.
Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, Granger CB, Moliterno DJ, Van de Werf F, Califf RM, Topol EJ, Armstrong PW; PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. Kaul P, et al. Among authors: van de werf f. J Am Coll Cardiol. 2001 Jul;38(1):64-71. doi: 10.1016/s0735-1097(01)01307-9. J Am Coll Cardiol. 2001. PMID: 11451297 Free article.
759 results